Linda Prezioso
Adult Health · Rocky Mount, NCNPI 1225302961
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 349 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,577 and has fallen 78.0% since, to $347 in 2025. Among adult health clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 349 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$991
- Novo Nordisk$958
- AbbVie$454
- Lilly USA, LLC$450
- Amgen$441
- Boehringer Ingelheim$268
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,695100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 54 | $991 |
| Novo Nordisk | 72 | $958 |
| AbbVie | 25 | $454 |
| Lilly USA, LLC | 26 | $450 |
| Amgen | 30 | $441 |
| Boehringer Ingelheim | 16 | $268 |
| Pfizer | 15 | $242 |
| GSK | 14 | $233 |
| Merck | 13 | $197 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $184 |
| Bayer | 8 | $122 |
| Hikma Pharmaceuticals USA | 6 | $113 |
| Idorsia Pharmaceuticals US Inc | 6 | $110 |
| Sanofi-aventis U.S. LLC | 8 | $110 |
| Esperion Therapeutics, Inc. | 5 | $89 |
| Exact Sciences | 5 | $88 |
| Grifols USA, LLC | 4 | $79 |
| Amarin Pharma, Inc. | 4 | $61 |
| Abbott | 3 | $52 |
| Eisai Inc. | 3 | $48 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Eyevance Pharmaceuticals LLC | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| Corcept Therapeutics | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
| Cequr Corporation | 1 | $11 |
How this compares
$5,695 in reported general payments places this provider in the 90th percentile of 614 adult health providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $80,834 |
| FarxigaDapagliflozin Propanediol | 70 | $66,403 |
| EliquisApixaban | 67 | $61,346 |
| JardianceEmpagliflozin | 28 | $40,716 |
| MounjaroTirzepatide | 20 | $36,668 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $26,994 |
| KerendiaFinerenone | 26 | $24,237 |
| LinzessLinaclotide | 28 | $21,596 |
| TrulicityDulaglutide | 16 | $17,202 |
| Atrovent HfaIpratropium Bromide | 11 | $8,947 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $7,432 |
| MyrbetriqMirabegron | 11 | $6,576 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,687 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $3,828 |
| Sumatriptan Succinate | 29 | $3,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $958 | $80,83468 claims |
| AstraZenecaFarxiga | $991 | $66,40370 claims |
| PfizerEliquis | $242 | $61,34667 claims |
| Lilly USA, LLCMounjaro, Trulicity | $450 | $53,87036 claims |
| Boehringer IngelheimJardiance | $268 | $40,71628 claims |
| GSKTrelegy Ellipta | $233 | $26,99431 claims |
| AbbVieLinzess, Synthroid | $454 | $24,67070 claims |
| BayerKerendia | $122 | $24,23726 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $1,720156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 adult health providers in North Carolina.
Other adult health in Rocky Mount
- Robert DodgeRaleigh$311K
- Kimberly CampDurham$147K
- Henry VanpalaRaleigh$110K
- Jolene SpencerWashington$83K
- Felicia RichardsonGreenville$64K
- Anna BooneReidsville$51K
- Chaely MedleyChapel Hill$47K
- Ann ShumDurham$35K
- Amy HopkinsGreenville$31K
- Stephanie YatesDurham$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.